Physician profile
Michael Fackovec
NPI 1245231414
$6,911.29
in general payments reported to CMS, 2019-2025
24 companies · $568 in 2025
The $568 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $571 · 2020: $857 · 2021: $1,018 · 2022: $1,194 · 2023: $1,334 · 2024: $1,370 · 2025: $568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,271.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,299.99 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $953.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $880.06 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $630.00 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $461.71 | 2019-2024 | Repatha, Otezla |
| Abbvie INC. | $396.98 | 2021-2023 | |
| Abbott Laboratories | $330.55 | 2022-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $327.90 | 2019-2023 | Ozempic |
| Astellas Pharma US INC | $284.23 | 2019-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $254.57 | 2021-2023 | |
| Exact Sciences Corporation | $248.67 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $143.62 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $133.37 | 2019-2020 | |
| Allergan, INC. | $113.00 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.43 | 2022-2025 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $88.12 | 2019-2025 | Fluad, Flucelvax, Fluad Quadrivalent |
| Horizon Therapeutics Plc | $83.79 | 2020-2023 | Krystexxa |
| Biohaven Pharmaceuticals, INC. | $43.31 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $40.78 | 2022-2024 | Camzyos |
| Vanda Pharmaceuticals INC. | $24.06 | 2019 | |
| Sanofi Pasteur INC. | $19.96 | 2022 | |
| Medtronic, INC. | $19.76 | 2025 | Inceptiv |
| Takeda Pharmaceuticals U.S.A., INC. | $16.85 | 2020 | |
| Dexcom, INC. | $15.10 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Fackovec listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.